Quince Therapeutics (QNCX) Insider Senner Buys 2,700 Shares

Christopher Senner recently purchased 2,700 shares of QNCX on June 11, 2026. The transaction did not involve any cash exchange as the shares were acquired at a price of $0.0. This insider activity comes at a time when QNCX shares are trading at approximately $0.93.

Insider Buying and Selling at Quince Therapeutics, Inc.

Christopher Senner wasn't the only insider involved in recent transactions. On the same day, David Lamond also acquired 2,700 shares at a price of $0.0. Earlier, on May 18, 2026, Brigette Roberts, the Chief Corporate Affairs Officer, purchased a substantial 9,860,843 shares. Brendan Hannah, who serves as the CBO, COO, and CCO, sold 365,000 shares on January 23, 2026, while Charles Ryan, the President, bought 200,000 shares on the same date.

Other Institutional Activity in QNCX

Institutional activity around QNCX has been notable. Woodline Partners LP significantly reduced its holdings by 1,421,542 shares, leaving them with 520,000 shares valued at approximately $527,280. Millennium Management LLC also cut its stake by 939,980 shares, holding 250,372 shares worth about $253,877. In contrast, Shay Capital LLC initiated a position with 177,291 shares valued at roughly $179,773. Acadian Asset Management LLC increased its holdings dramatically by 157,775 shares, ending with 175,086 shares valued at $176,000.

Analysts Set New Price Targets

Analysts have shown a positive outlook on QNCX. On January 29, 2026, D. Boral Capital maintained its 'buy' rating with a price target of $5.00. JMP Securities also maintained a 'buy' rating, setting a higher target of $8.00 on August 12, 2025. Earlier, Oppenheimer initiated coverage with a 'buy' rating and a $10.00 target on March 24, 2025, reflecting confidence in the company's future performance.

Bottom Line

Christopher Senner's recent purchase of QNCX shares highlights ongoing interest in the company from insiders. While the shares were acquired at no cost, the transaction reflects confidence in QNCX's potential. Institutional activity around QNCX shows varied strategies, with some firms reducing their stakes while others are increasing or initiating positions. Analysts remain optimistic, with several maintaining 'buy' ratings and setting ambitious price targets. As always, it's important to consider that insider and institutional moves can be based on various factors, and these filings are backward-looking, reflecting past decisions.